Literature DB >> 7806032

Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.

S V Peña1, M F Melhem, A I Meisler, C A Cartwright.   

Abstract

BACKGROUND/AIMS: The cellular oncogene c-yes and its viral homologue v-yes (the transforming gene of Yamaguchi 73 and Esh avian sarcoma viruses) encode 62-kilodalton, cytoplasmic, membrane-associated, protein-tyrosine kinases. For the related Src kinase, a close correlation exists between elevated kinase activity and cell transformation. Previously, we observed elevated Yes activity in many human colon carcinomas. Colonic neoplasia provides an opportunity to study tumor progression because most carcinomas arise from adenomas, which in turn arise from normal epithelia. The malignant potential of adenomas varies with size, histology, and degree of dysplasia. Large adenomas (> or = 2 cm) with villous architecture and severe dysplasia are most likely to develop carcinoma.
METHODS: To determine whether Yes is activated in premalignant lesions of the colon, we measured its in vitro protein-tyrosine kinase activity in 21 colonic adenomas from 17 patients.
RESULTS: Activity of Yes in adenomas at greatest risk for cancer was significantly greater (12- or 14-fold as measured by enolase or autophosphorylation, respectively) than activity in adjacent normal mucosa. Moreover, villous structure, large size (> or = 2 cm), or severe dysplasia correlated with elevated Yes activity.
CONCLUSIONS: The activity of Yes is elevated in adenomas that are at greatest risk for developing cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7806032     DOI: 10.1016/0016-5085(95)90015-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas.

Authors:  S Eggstein; G Manthey; T Hirsch; F Baas; B U Specht; E H Farthmann
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

2.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

3.  Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.

Authors:  R J Alexander; A Panja; E Kaplan-Liss; L Mayer; R F Raicht
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

Review 4.  EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.

Authors:  Jyoti Nautiyal; Shailender Singh Kanwar; Adhip P N Majumdar
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

5.  Analysis of signaling protein kinases in human colon or colorectal carcinomas.

Authors:  L L Licato; D A Brenner
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

6.  Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

Authors:  Ching Hang Wong; Frederick L Baehner; Danislav S Spassov; Deepika Ahuja; Donghui Wang; Byron Hann; Jimmy Blair; Kevan Shokat; Alana L Welm; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

7.  Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Authors:  Audrey Sirvent; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

8.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

Review 9.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

10.  MicroRNA-145 targets YES and STAT1 in colon cancer cells.

Authors:  Lea H Gregersen; Anders B Jacobsen; Lisa B Frankel; Jiayu Wen; Anders Krogh; Anders H Lund
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.